Invitrogen, ABI Merger Valued at $5.1 Billion | GenomeWeb

NEW YORK (GenomeWeb News) – The November merger of Invitrogen and Applied Biosystems to form Life Technologies has been valued at $5.1 billion, down from the initial estimate of $6.7 billion.

Life Technologies disclosed in a filing with the US Securities and Exchange Commission yesterday that the value of Life Technologies shares issued in the transaction was around $1.8 billion, while the cash portion of the deal was roughly $3.2 billion. ABI shareholders received a total of approximately 80.8 million of the combined company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.